European Association for the Study of Diabetes
Lisbon • September 12 - 16, 2011
--------------------------------------------------------------------------------
Gliptin Tx Works Long-Term for Glycemic Control
LISBON -- Long-term treatment of type 2 diabetes with dipeptidyl peptidase-4 (DPP-4) inhibitors for two years appeared to maintain improvement in glycosylated hemoglobin A1c levels, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
Debate Brings Incretin Risks to Forefront
LISBON -- Whispered concerns about a higher risk of certain cancers linked with incretin therapies for diabetes have become more audible after a debate here between top researchers.
[Ссылки доступны только зарегистрированным пользователям ]
Meta-Analysis Confirms Value of CGM in Type 1 Diabetes
LISBON -- Despite its limitations, continuous glucose monitoring (CGM) appears to improve glycemic control compared with self-monitoring in type 1 diabetes patients, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
Closed-loop System on Par With Open-loop for Glucose Control
LISBON -- A bihormonal closed-loop system in patients with diabetes that delivers rescue glucagon as well as insulin may be comparable with open-loop administration of the two hormones, researchers said here.
[Ссылки доступны только зарегистрированным пользователям ]
Breast Cancer in Diabetes May Be Artifactual
LISBON -- An apparent risk of breast cancer in postmenopausal women recently diagnosed with type 2 diabetes may in fact be related to detection bias, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
’Gliptin’ Diabetes Drugs May Be Heart Savers
LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment with the so-called gliptin class appears to protect the heart.
[Ссылки доступны только зарегистрированным пользователям ]
Contest Offers $100K for "New Insulin"
LISBON -- One diabetes advocacy group is betting that the next big thing in treatment, especially for type 1 disease, will come not from within the field, but from putting together many heads from various disciplines.
[Ссылки доступны только зарегистрированным пользователям ]
Novel Drug BRIGHTENs Diabetes Research
LISBON -- The investigational drug ipragliflozin improved glycemic control and decreased body weight and blood pressure, according to the phase III BRIGHTEN study.
[Ссылки доступны только зарегистрированным пользователям ]
Once-Weekly Exenatide Flops Against Liraglutide
LISBON -- A trial failed to prove that once-weekly injections of exenatide (Bydureon) were equal to daily injections of liraglutide (Victoza) in reducing glycosylated hemoglobin A1c in type 2 diabetes patients, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
No Microvascular Benefit With Intense BP, Glucose Control
LISBON -- Aggressively lowering blood pressure and blood glucose together won’t provide any microvascular benefits to type 2 diabetes patients, researchers said here.
[Ссылки доступны только зарегистрированным пользователям ]
Biomarkers May Predict CAD, Death in Diabetics
LISBON -- Two biomarkers may be associated with cardiovascular events and death in type 2 diabetes patients, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
Liraglutide Plus Insulin Does Not Add Weight
LISBON -- The addition of insulin to the treatment regimen of type 2 diabetes patients on liraglutide (Victoza) doesn’t wipe out previously seen weight loss -- and insulin appears to help these patients achieve glycemic control, researchers said here.
[Ссылки доступны только зарегистрированным пользователям ]
Gestational Diabetes Guidelines Controversial
LISBON -- International guidelines on screening for gestational diabetes that will likely raise the prevalence of the condition have sparked questions over appropriate diagnostic tools and cost efficacy, researchers said here.
[Ссылки доступны только зарегистрированным пользователям ]
Intensive Glucose Control Cuts Renal Risks
LISBON -- Intensive glucose-lowering may protect against end-stage renal disease (ESRD) in diabetic patients, according to an analysis of data from the ADVANCE trial.
[Ссылки доступны только зарегистрированным пользователям ]
Diabetes, MI, Feeling Bad Add Up to Shorter Life
LISBON -- Men with type 2 diabetes and an acute myocardial infarction who score lower on quality-of-life measures have a greater mortality risk than other men with these conditions whose scores indicate they feel better about their health, researchers reported here.
[Ссылки доступны только зарегистрированным пользователям ]
Diabetes Estimate Now 366 Million
LISBON -- About 366 million people worldwide have diabetes, according to the latest figures from the International Diabetes Federation, released in advance of a United Nations summit on non-communicable diseases in New York next week.
[Ссылки доступны только зарегистрированным пользователям ]
Hot Controversies, but No Hot-Line Sizzlers
LISBON -- Though there’s "no major endpoint trial" being presented at this year’s European Association for the Study of Diabetes meeting here, executive director Viktor Joergens, MD, said there will be plenty of debate over several recent controversies.
[Ссылки доступны только зарегистрированным пользователям ]
|